We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Protein Expression in Samples From Young Patients With Rhabdomyosarcoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01426945
First Posted: September 1, 2011
Last Update Posted: May 18, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
August 31, 2011
September 1, 2011
May 18, 2016
November 2011
May 2016   (Final data collection date for primary outcome measure)
RMS protein expression profile
Same as current
Complete list of historical versions of study NCT01426945 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Protein Expression in Samples From Young Patients With Rhabdomyosarcoma
Evaluating Candidate Protein Expression in Human Rhabdomyosarcoma (RMS)

RATIONALE: Studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This research trial studies protein expression in samples from young patients with rhabdomyosarcoma.

OBJECTIVES:

  • To measure the protein expression of candidate proteins in human rhabdomyosarcoma (RMS) tumor samples.

OUTLINE: Archived tumor tissue samples are analyzed for protein expression (i.e., Notch1, Hey1, FGFR4, and Sp1) by IHC techniques and standard commercially available antibodies. Candidate proteins are then correlated with each patient age, gender, rhabdomyosarcoma (RMS) tumor stage, and RMS tumor subtype.

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:
Tumor tissue
Non-Probability Sample
Children with rhabdomyosarcoma (RMS) enrolled in the Children's Oncology Group clinical trials
Sarcoma
  • Genetic: protein expression analysis
  • Other: immunohistochemistry staining method
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
77
Not Provided
May 2016   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Tumor tissue samples from children with rhabdomyosarcoma (RMS) enrolled in the Children's Oncology Group clinical trials

    • Alveolar rhabdomyosarcoma (ARMS)
    • Embryonal rhabdomyosarcoma (ERMS)

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01426945
ARST11B3
COG-ARST11B3 ( Other Identifier: Children's Oncology Group )
ARST11B3 ( Other Identifier: Children's Oncology Group )
NCI-2011-03534 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
No
Not Provided
Not Provided
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Corinne M. Linardic, MD, PhD Duke Cancer Institute
Children's Oncology Group
May 2016